What is CAR-T Cell Therapy?
A personalized cellular therapy approach
The information on this page is for general informational purposes. CAR-T cell therapy eligibility is determined only by the relevant specialist physician and multidisciplinary council evaluation. This page does not constitute medical advice.
A personalized cellular therapy approach
CAR-T cell therapy is a cellular therapy approach based on preparing the patient's own T cells in the laboratory to recognize certain cancer cells and then returning them to the patient.
The aim of the treatment is to help the reprogrammed T cells recognize the targeted cells and generate an immune response. The target to be applied may vary depending on the type of disease and treatment programme.
The CAR-T process is a multidisciplinary process requiring the coordination of hematology/oncology, cell processing/manufacturing, infectious diseases, intensive care, pharmacy, nursing and support units.
The process at a glance
Cell collection
Cell engineering
Infusion
Close monitoring
Basic stages of the CAR-T process
The CAR-T process consists of seven basic stages. Each stage requires planning specific to the patient and coordination between different units.
Eligibility evaluation
Diagnosis, previous treatments, current clinical status and tests are reviewed. If necessary, additional information or tests may be requested.
Leukapheresis
T cells are collected through a special blood cell collection procedure. Before this procedure, vascular access, blood values, infection risk and general condition are evaluated.
Cell engineering and quality controls
The collected cells go through defined manufacturing and quality control processes. The duration may vary depending on the patient and operational planning. During this period, the patient's current disease treatment is managed only according to the joint plan of the relevant physicians.
Pre-treatment preparation
In some patients, a preparation treatment called lymphodepletion may be applied before cell infusion. The necessity, content and timing of this approach are determined by the specialist team.
CAR-T cell infusion
The prepared cells are given to the patient intravenously. After the infusion, the patient is closely monitored according to centre protocols and clinical need.
Close clinical monitoring
After treatment, side effects and clinical status are closely monitored. An early diagnosis and intervention plan is applied for possible side effects.
Post-discharge follow-up
After discharge, check-ups, laboratory monitoring, infection protection, medications and emergency referral criteria are communicated to the patient/family. For patients coming from outside the city or abroad, the follow-up plan is organised as much as possible in coordination with their own physicians.
Who can be evaluated for CAR-T?
CAR-T cell therapy can be evaluated for specific diseases and clinical situations. Eligibility is not determined only by the name of the disease. The following headings are reviewed together:
Definitive diagnosis and subtype of the disease
Current status of the disease
Previous treatments and response to treatment
Organ functions and performance status
Active infection or comorbidities
Ability to provide the follow-up conditions required during and after treatment
Why is close monitoring important?
After CAR-T cell therapy, conditions such as fever, blood pressure changes, respiratory complaints, neurological findings or infections may develop. Therefore, close clinical monitoring is required during the treatment process and in the early period.
The physician team explains in detail the possible benefits and treatment-related risks to the patient and family. Which findings require emergency referral should be shared in writing and verbally before discharge.
Safety note: In case of symptoms such as fever, shortness of breath, chest pain, altered consciousness, newly developing weakness, severe headache or rapid deterioration in general condition, emergency health evaluation should be carried out according to the patient's plan.
When should you seek emergency help?
The following symptoms after CAR-T therapy may require emergency medical evaluation:
- Fever
- Shortness of breath
- Chest pain
- Altered consciousness or fainting
- Newly developing weakness
- Severe headache
- Rapid deterioration in general condition
Learn more about the treatment journey
See the full patient journey from eligibility evaluation to follow-up in your own country.